MARKET

SELB

SELB

Selecta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.400
-0.080
-1.79%
Pre Market: 4.370 -0.03 -0.68% 08:58 09/24 EDT
OPEN
4.500
PREV CLOSE
4.480
HIGH
4.529
LOW
4.330
VOLUME
4
TURNOVER
--
52 WEEK HIGH
5.70
52 WEEK LOW
1.470
MARKET CAP
506.35M
P/E (TTM)
-10.4762
1D
5D
1M
3M
1Y
5Y
Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses...
GlobeNewswire · 3d ago
BRIEF-Selecta Biosciences Announces Appointment Of Kevin Tan As Chief Financial Officer
reuters.com · 4d ago
Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR(TM) platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta's Chief Executive O...
GlobeNewswire · 09/09 12:00
Selecta Biosciences, Cyrus Biotechnology Collaborating to Create Engineered Therapeutic Proteins
MT Newswires · 09/08 12:34
BRIEF-Selecta, Cyrus Biotechnology Collaborate To Create Novel Engineered Therapeutic Proteins
reuters.com · 09/08 12:21
DelveInsight Estimates a Promising Gout Pipeline Owing to an Expected Entry of Novel Therapeutic Agents
DelveInsight Estimates a Promising Gout Pipeline Owing to an Expected Entry of Novel Therapeutic Agents
GlobeNewswire · 09/01 00:00
Acuta Capital Partners, Llc Buys BCLS Acquisition Corp, Vincerx Pharma Inc, Cyteir Therapeutics ...
GuruFocus News · 08/18 20:38
Rainbows and Unicorns: Selecta Biosciences, Inc. (NASDAQ:SELB) Analysts Just Became A Lot More Optimistic
Celebrations may be in order for Selecta Biosciences, Inc. ( NASDAQ:SELB ) shareholders, with the analysts delivering a...
Simply Wall St. · 08/17 10:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SELB. Analyze the recent business situations of Selecta through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SELB stock price target is 8.67 with a high estimate of 13.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 54.18M
% Owned: 47.08%
Shares Outstanding: 115.08M
TypeInstitutionsShares
Increased
37
4.95M
New
19
894.75K
Decreased
29
4.28M
Sold Out
15
3.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
Carrie Cox
President/Chief Executive Officer/Director
Carsten Brunn
Chief Financial Officer/Chief Accounting Officer
Kevin Tan
Chief Operating Officer/Senior Vice President
Lloyd Johnston
Chief Human Resource Officer
Kristen Baldwin
Chief Scientific Officer
Takashi Kishimoto
Other
Peter Traber
Director
Nishan de Silva
Independent Director
Goran Ando
Independent Director
Timothy Barabe
Independent Director
Scott Myers
Independent Director
Aymeric Sallin
Independent Director
Timothy Springer
Independent Director
Patrick Zenner
No Data
About SELB
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Webull offers kinds of Selecta Biosciences Inc stock information, including NASDAQ:SELB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SELB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SELB stock methods without spending real money on the virtual paper trading platform.